Is the Tdap Vaccine Necessary? Risks of Skipping

Skipping the Tdap vaccine leaves you exposed to three serious bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough). Each carries real risk of hospitalization, lasting complications, or death, and the dangers are especially acute for newborns, older adults, and anyone whose immunity has faded since childhood. The vaccine is one of the few that matters not just for your own protection but for the survival of infants too young to be vaccinated themselves.

What Tdap Protects Against

Tdap is a combination booster vaccine targeting three diseases. Tetanus is caused by a toxin-producing bacterium found in soil, dust, and manure. It does not spread person to person; you pick it up through breaks in the skin, and the toxin attacks the nervous system, causing severe muscle spasms and lockjaw. A systematic review of hospitalized adult tetanus patients found an overall mortality rate of about 32%.¹ U.S. surveillance data paint a somewhat better picture because of intensive-care access: among cases reported from 2009 to 2023, the case fatality rate was around 12%, but nearly two-thirds of hospitalized patients required ICU care and over 40% needed mechanical ventilation.² Recovery can take months because the toxin irreversibly binds to nerve terminals, and the body has to grow new neuromuscular connections.

Diphtheria produces a thick membrane in the throat that can block the airway entirely. In a retrospective study of children hospitalized with diphtheria, the most common features were bull neck swelling, fever, sore throat, and a pseudomembrane in the throat. Nearly half developed respiratory failure, and roughly one in five developed myocarditis, inflammation of the heart muscle.³ A case report of a 16-year-old with respiratory diphtheria documented fulminant myocarditis with cardiac arrhythmias and neurological complications, underscoring how quickly the disease can become life-threatening even in previously healthy teenagers.⁴ Diphtheria is rare in wealthy countries precisely because of vaccination, but it still circulates globally, and cases appear in under-vaccinated communities.

Pertussis, or whooping cough, is highly contagious and spreads through respiratory droplets. In adults, it often presents as a prolonged, violent cough lasting weeks. In infants, it can be fatal. Most pertussis deaths occur in babies younger than three months, before they have received their own vaccine doses.⁵

Why Immunity Fades and Boosters Matter

Even if you were fully vaccinated as a child, protection from the pertussis component does not last a lifetime. A large study of vaccine effectiveness found that protection was about 80-84% in the first three years after the last dose but dropped to roughly 62% by four to seven years and around 41% at eight or more years out. The risk of pertussis infection climbed about 27% per year since the last dose.⁶ This waning is especially pronounced in people who received the newer acellular pertussis vaccines (the “aP” in Tdap) rather than the older whole-cell versions used before the late 1990s.

Antibody measurements tell a similar story. One long-term study found that antibodies against pertussis toxin, the key target, declined back to pre-vaccination levels roughly five years after a booster, even though antibodies against other pertussis components stayed elevated for up to ten years.⁷ Next-generation recombinant pertussis vaccines show some promise in maintaining antibodies longer: five years after a booster with a genetically detoxified pertussis vaccine, pertussis-toxin-neutralizing antibodies remained two and a half to three times higher than pre-vaccination levels.⁸ But current Tdap vaccines still require periodic reboosting because the protection they offer is real but temporary.

For tetanus and diphtheria, the WHO recommends a total of six doses across childhood and adolescence for long-lasting immunity, with additional boosters to maintain protection.⁹ If you have not kept up with boosters and step on a rusty nail, an emergency room visit might include both a tetanus booster and an injection of tetanus immunoglobulin, but that is emergency management of a problem that vaccination prevents in the first place.

Tdap During Pregnancy Protects Newborns

One of the most consequential uses of Tdap is during pregnancy. Babies cannot receive their first pertussis vaccine dose until they are two months old, leaving a dangerous window during which they are completely unprotected. When a pregnant person receives Tdap during the third trimester, their body produces antibodies that cross the placenta and provide passive immunity to the newborn. A study of over 148,000 newborns found that maternal Tdap was about 91% effective at preventing pertussis in infants during the first two months of life, dropping to about 69% effectiveness across the entire first year.¹⁰

A separate case-control study estimated that third-trimester Tdap vaccination was roughly 78% effective overall at preventing infant pertussis, and its effectiveness rose to about 91% against cases severe enough to require hospitalization.¹¹ Research on placental antibody transfer found that prenatal Tdap did not interfere with how efficiently antibodies crossed the placenta; it simply ensured that the mother had more protective antibodies available to transfer, resulting in a higher proportion of infants born with protective antibody levels.¹²

A decision analysis found that vaccination during pregnancy could reduce infant pertussis cases by about 33%, hospitalizations by 38%, and deaths by 49%, far exceeding the impact of postpartum vaccination strategies.¹³ Another modeling study found that vaccinating during pregnancy would prevent nearly twice as many infant hospitalizations as the “cocooning” approach of vaccinating only close contacts after birth.¹⁴ This is why health authorities recommend Tdap in every pregnancy, ideally between weeks 27 and 36, regardless of whether the parent was vaccinated before.

Is Tdap Safe During Pregnancy?

Multiple large studies have examined prenatal Tdap and found a reassuring safety profile. A large retrospective study at Kaiser Permanente Southern California found no increased risk of preterm delivery, small-for-gestational-age babies, stillbirth, placental abruption, or neonatal death. Modest statistical associations were seen with preeclampsia and intrauterine infection diagnoses, but the researchers noted these increases were consistent with background trends rising across all pregnant women at that health system, and the associations fell well below pre-specified thresholds for a genuine safety signal.¹⁵

A separate pregnancy safety study found no increase in preterm labor, preeclampsia, fetal growth restriction, gestational diabetes, placental abruption, or chorioamnionitis. The vaccine actually appeared to have a protective effect against preeclampsia with severe features, preterm labor, and preterm delivery.¹⁶ A third study focusing specifically on chorioamnionitis found no association between prenatal Tdap and that infection or related infant outcomes.¹⁷ Taken together, these studies include hundreds of thousands of pregnancies and consistently show no meaningful harm to mother or baby.

Side Effects and Rare Adverse Events

The most common side effects of Tdap are what you would expect from any vaccine: soreness at the injection site, mild swelling, and occasionally a low-grade fever or fatigue. These resolve within a day or two. A rare but more dramatic reaction is the Arthus reaction, a localized immune response that produces significant swelling, pain, induration, and occasionally tissue damage at the injection site. It is a type of hypersensitivity reaction related to pre-existing antibodies and occurs more often with repeat doses; roughly half of reported cases in published literature happened after the second injection in a series.¹⁸ This is one reason guidelines recommend spacing Tdap boosters rather than getting them too frequently.

For more serious neurological events, a large active surveillance study covering over 660,000 Tdap doses found no evidence of an association with encephalopathy, encephalitis, meningitis, paralytic syndromes, seizures, or cranial nerve disorders when compared to the standard Td vaccine.¹⁹ More recently, a tree-based scan statistic analysis of the Vaccine Safety Datalink did detect a statistical signal between Tdap and Guillain-Barré syndrome, though such signals flag potential associations for closer investigation rather than confirming causation.²⁰ The absolute risk, if any, is vanishingly small compared to the risks of the diseases themselves.

The Acellular Vaccine and the Transmission Problem

There is a genuine and fascinating limitation of current pertussis vaccines that is worth understanding. The acellular pertussis vaccines used today (the “aP” in DTaP for children and Tdap for adolescents and adults) replaced earlier whole-cell vaccines that had more side effects. While acellular vaccines are effective at preventing you from getting seriously sick, research in nonhuman primates found that vaccinated baboons were protected from severe pertussis symptoms but could still be colonized by the bacteria and transmit it to unvaccinated contacts.²¹

Mouse studies have added detail to this picture: acellular vaccines protect the lungs well but do not prevent colonization of the nasal passages, and they may actually prolong nasal carriage by suppressing the mucosal immune memory that would naturally clear the bacteria from the nose.²² The old whole-cell vaccines triggered a different type of immune response that was better at clearing colonization. The acellular versions produce higher antibody levels with fewer side effects, but they generate a different immune profile that is less effective at stopping the bacteria from living in your nose and throat and spreading to others.²³

This is not an argument against getting vaccinated. You are still far less likely to get severely ill if you are vaccinated, and high vaccination rates in the population still reduce overall transmission by limiting severe, symptomatic cases that spread the most bacteria. But it does help explain why pertussis has not been eliminated despite high vaccine coverage, and why researchers are actively working on next-generation vaccines that might do a better job of blocking transmission entirely.

Why Pertussis Keeps Coming Back

Pertussis outbreaks continue to occur in waves every few years, even in countries with good childhood vaccination programs. Several factors converge: waning immunity from acellular vaccines, the transmission gap described above, and gaps in vaccine coverage. Research has linked higher pertussis incidence to interruptions in vaccine coverage associated with anti-vaccine movements, the ease of obtaining non-medical vaccine exemptions at the state level in the United States, and geographic clustering of unvaccinated families at the community level.²⁴ When clusters of unvaccinated people form, pertussis can circulate more easily, and the people most likely to die are infants who have had no doses yet.

Adults often do not realize they have pertussis because in a partially immune person it can look like nothing more than a persistent cough. They then unwittingly pass it to vulnerable contacts. This is why adult boosters are not just about personal protection. They reduce the severity of infections and decrease the amount of bacteria a person sheds, lowering the chance of spreading the disease to a baby or an elderly relative for whom the infection could be devastating.

Older Adults and Healthcare Workers

Pertussis in older adults is more dangerous than many people assume. Complications can include rib fractures from violent coughing, pneumonia, weight loss, and urinary incontinence. Those with chronic lung or heart conditions face especially high risks. Vaccine coverage in older adults tends to be low, and experts have called for strengthening and harmonizing immunization guidelines, having healthcare professionals more actively recommend boosters, and improving public awareness of pertussis burden in aging populations.²⁵

Healthcare workers are a priority group for Tdap because they are more likely to encounter pertussis on the job and could pass it to high-risk patients, including newborns in neonatal units and immunocompromised individuals. Acellular pertussis boosters have been shown to be safe, immunogenic, and effective in this population.²⁶ An Australian study of healthcare workers found that pertussis immune memory persisted for up to twelve years after a Tdap booster, and there was no evidence that booster responses waned faster with each subsequent dose, supporting the recommendation to revaccinate healthcare workers at least every ten years.²⁷

Wound Management and Tetanus

Tetanus risk is not limited to stepping on a rusty nail, the classic scenario everyone pictures. National wound-management guidance classifies several types of injuries as tetanus-prone, including wounds or burns where surgical treatment is delayed more than six hours, deep puncture wounds, injuries involving contact with soil or manure, wounds containing foreign bodies, compound fractures, and wounds in patients showing signs of systemic infection.²⁸ Animal bites also qualify. If you show up at an emergency department with one of these injuries and your vaccination history is incomplete or unknown, you will likely receive both a tetanus-containing vaccine and tetanus immunoglobulin, which provides immediate short-term protection while the vaccine stimulates your own immunity.

U.S. surveillance data show that most tetanus deaths now occur in adults over 65, a group more likely to have incomplete vaccination or waned immunity.² Risk factors for dying from tetanus include age over 40, a short incubation period, the presence of autonomic dysfunction (where the nervous system loses control of heart rate and blood pressure), and the need for mechanical ventilation.¹ Unlike pertussis, surviving tetanus does not give you natural immunity, so vaccination is important even for people who have recovered from the disease.

What Skipping Actually Costs

The economic analysis of Tdap vaccination during pregnancy illustrates how lopsided the risk-benefit calculation really is. A cost-effectiveness study estimated that prenatal maternal vaccination costs about $114,000 per quality-adjusted life-year saved, which falls within the range considered cost-effective by WHO criteria for the United States. By contrast, postpartum vaccination strategies were far less cost-effective, and vaccinating a second parent provided marginal additional benefit at substantially higher cost.²⁹

These numbers are really about hospitalizations avoided and infant lives saved. A hospitalized case of pertussis in an infant involves days in a pediatric ICU, mechanical ventilation, and the real possibility of brain damage from oxygen deprivation during coughing spells. A hospitalized case of tetanus involves weeks of ICU care, sedation, and ventilator support while the toxin slowly clears. The cost of a single Tdap shot is trivial compared to the cost of treating any of these diseases, and the diseases cannot simply be treated with antibiotics once they are advanced. Tetanus antitoxin cannot reverse damage already done. Diphtheria antitoxin works best before the toxin has bound to tissues. For pertussis in very young infants, antibiotics can limit spread but do not change the course of the illness once the coughing paroxysms have set in. Prevention through vaccination remains far more effective than trying to treat these infections after the fact.

Diphtheria in an Era of Low Awareness

Diphtheria gets less attention than tetanus or pertussis in vaccine discussions, partly because it has become so rare in high-income countries that most physicians have never seen a case. But this rarity is a product of vaccination, not of the disease disappearing. The bacterium still circulates, and when it finds unvaccinated or under-vaccinated populations, it can cause outbreaks. A case report from the United Kingdom documented a patient who developed life-threatening airway obstruction from thick purulent discharge and subglottic swelling caused by diphtheria, requiring emergency airway management.³⁰ These cases serve as reminders that the disease has not gone away; it has been held at bay by vaccination, and letting coverage slip means inviting it back.

Migration patterns add another dimension. People arriving from regions where diphtheria is endemic may not have completed a vaccination series, and outbreaks in refugee populations have occurred in Europe in recent years. The case of the 16-year-old Afghan patient mentioned earlier specifically highlights the importance of verifying vaccination status in migrant populations.⁴ For the general public, the lesson is simpler: if you are unsure whether you have been vaccinated against diphtheria, a single Tdap booster can close that gap.

1
PubMed. Mortality and risk factors in hospitalised adult patients with tetanus: a systematic review and meta-analysis
2
Morbidity and Mortality Weekly Report. Tetanus Surveillance — United States, 2009–2023
3
PubMed Central. Clinical features, prognosis, and treatment outcomes of diphtheria in children: a retrospective cohort study at children’s hospital, Sukkur
4
JACEP Open. Respiratory Diphtheria in a 16-Year-Old Who Developed Multiple Life-Threatening Complications
5
Clinical Infectious Diseases. Risk Factors Associated With Infant Deaths From Pertussis: A Case-Control Study
6
PubMed Central. Effectiveness of pertussis vaccination and duration of immunity
7
Vaccine. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA
8
JAMA Network Open. Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines
9
PubMed. Are current UK tetanus prophylaxis procedures for wound management optimal?
10
PubMed. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis
11
PubMed Central. The Impact of the U.S. Maternal Tdap Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-control Evaluation
12
PubMed Central. Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status
13
PubMed. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis
14
Vaccine. Cost–benefit of the introduction of new strategies for vaccination against pertussis in Spain: Cocooning and pregnant vaccination strategies
15
Vaccine. Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy
16
Vaccine. Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine
17
PubMed Central. Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes
18
PubMed Central. The vaccines-associated Arthus reaction
19
Vaccine. An assessment of the safety of adolescent and adult tetanus–diphtheria–acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink
20
Vaccine. Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barré syndrome in the Vaccine Safety Datalink
21
PubMed Central. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
22
PubMed Central. Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage
23
PubMed Central. Whole-Cell and Acellular Pertussis Vaccines: A Narrative Review of Biological, Clinical, Safety and Programmatic Evidence, with Implications for Poland
24
Cambridge University Press. Perplexities of pertussis: recent global epidemiological trends and their potential causes
25
PubMed Central. Improving vaccination rates in older adults and at-risk groups: focus on pertussis
26
PubMed Central. Pertussis vaccination for health care workers
27
PubMed. An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers
28
PubMed Central. The importance of tetanus risk assessment during wound management
29
American Journal of Epidemiology. Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States
30
PubMed Central. A Case of Life-Threatening Airway Obstruction Caused by Acute Diphtheria Infection in the United Kingdom